AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ekso Bionics shares rise 27.81% premarket after securing exclusive U.S. distribution deal for MediTouch's BalanceTutor rehabilitation system.
ByAinvest
Thursday, Dec 4, 2025 8:06 am ET1min read
Ekso Bionics surged 27.81% in premarket trading following the announcement that it secured an exclusive U.S. distribution agreement for MediTouch’s BalanceTutor rehabilitation system. The BalanceTutor, a 4D perturbation treadmill designed to simulate balance challenges for patients, aligns with Ekso’s focus on medical exoskeleton technology. The partnership, described as synergistic by CEO Scott Davis, expands Ekso’s product offerings and market reach in rehabilitation solutions. Investors reacted strongly to the news, with the stock’s premarket gain exceeding the 20% rise noted in prior reporting. The deal underscores Ekso’s strategy to leverage complementary technologies within its enterprise health portfolio, enhancing its competitive position in the medical robotics sector.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet